Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155678 | 1.00 | PIK3CD (0.46) | PIK3CDRECQLHPGDUSP2SMN1; SMN2 | |
| SCHEMBL25042385 | 0.92 | MEN1 (0.48) | PIK3CDRECQLHPGDUSP2SMN1; SMN2 | |
| SCHEMBL7387538 | 0.91 | RECQL (0.51) | RECQLHPGDUSP2SMN1; SMN2EPHX1 | |
| SCHEMBL30987099 | 0.88 | USP2 (0.56) | PIK3CDRECQLHPGDUSP2SMN1; SMN2 | |
| SCHEMBL13167071 | 0.88 | NR1H2 (0.46) | PIK3CDRECQLHPGDUSP2SMN1; SMN2 | |
| SCHEMBL30987034 | 0.85 | MAPT (0.40) | PIK3CDRECQLHPGDUSP2SMN1; SMN2 | |
| SCHEMBL2878174 | 0.83 | PPM1D (0.34) | PIK3CDRECQLSMN1; SMN2USP30 | |
| SCHEMBL21954152 | 0.83 | PPM1D (0.34) | PIK3CDRECQLSMN1; SMN2USP30 | |
| SCHEMBL30918741 | 0.83 | EPHX2 (0.35) | PIK3CDSMN1; SMN2EPHX1PIK3CAPIK3CB | |
| SCHEMBL2873724 | 0.83 | PPM1D (0.34) | PIK3CDRECQLSMN1; SMN2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-8329741-B2 | Substituted pyrrolidine compounds with central nervous system activity | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329741-B2 | Substituted pyrrolidine compounds with central nervous system activity | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090048329-A1 | Substituted Pyrrolidine Compounds With Central Nervous System Activity | NIH-DEITR | 2009-02-19 | — | — | US | disclosed |
| US-20090048329-A1 | Substituted Pyrrolidine Compounds With Central Nervous System Activity | NIH-DEITR | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048329-A1 | Substituted Pyrrolidine Compounds With Central Nervous System Activity | SLC6A3, SLC18A2, SLC6A2 | PIK3CD 1685/4885RECQL 4390/4885HPGD 2321/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIK3CD 1571/4885RECQL 812/4885HPGD 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.